Enterprise Expansion Dario is expanding through Fortune 50 contracts and large employer partnerships, including a recent agreement covering more than 100,000 employees and a major health insurer via Amwell. This indicates strong appetite for integrated cardiometabolic care platforms at scale and suggests cross-sell opportunities across large corporate and payer networks.

GLP-1 Integrated Offering The July 2026 launch of the Integrated GLP-1 Program with Beluga Health creates a new end-to-end solution combining digital care with provider-backed clinical oversight. This opens up upsell opportunities to employers, health plans, and direct-to-consumer channels seeking comprehensive GLP-1 pathways and reimbursement-ready programs.

AI Engine Upsell DarioIQ is positioned to lift recurring revenue by enabling higher engagement and retention, with projected 10–15% ARRC growth from existing customers. This presents a compelling expansion pitch to current enterprise clients aiming to deepen outcomes and ROI through advanced personalization.

Channel Partnerships Strategic collaboration with Amwell and insurer networks demonstrates a channel-led growth model that accelerates scale and access to new insured lives. Sales efforts should target payer and telehealth partnerships, highlighting cost-of-care reductions and measurable cardiometabolic outcomes.

Multi-Condition Platform Dario’s broad platform covers wellbeing to chronic condition management, backed by billions of data points and consumer experience. This versatility enables cross-sell across multiple conditions within existing accounts and positions Dario as a centralized digital health solution for employers and health plans seeking integrated care.